CLINICAL_TRIALS
trial_result
· 2020-04-17
Clinical Trial Update: Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD [Phase 2]
Summary
Phase II trial investigating natalizumab plus prednisone for initial therapy of acute GI graft-versus-host disease has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Graft Versus Host Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-04-17